Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $24.11 and last traded at $24.57, with a volume of 131556 shares traded. The stock had previously closed at $25.03.
Analysts Set New Price Targets
MTSR has been the subject of several analyst reports. Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an "outperform" rating for the company. Bank of America started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating on the stock. Finally, Guggenheim began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price target for the company.
Read Our Latest Research Report on MTSR
Metsera Stock Performance
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
